Here are the S-3 shelf registrations from Agios Pharmaceuticals, Inc. (AGIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow AGIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGIO filings page.
Agios Pharmaceuticals, Inc. has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, allowing it to offer debt securities, common stock, preferred stock, warrants and units from time to time after effectiveness. Specific terms for each issuance will be set in separate prospectus supplements.
Agios is a commercial-stage biopharmaceutical company focused on rare disease treatments, with a foundation in hematology. It plans to use any net proceeds primarily for general corporate purposes, including working capital, research and development, clinical and commercialization expenses, potential acquisitions or investments, and possible repayment or refinancing of debt.